Objectives: Broad-spectrum antimicrobial resistance in Pseudomonas aeruginosa (PSA) isolates is a growing concern as our therapeutic options have become significantly limited. Although ceftolozane/tazobactam (C/T) has been shown to be highly active against MDR PSA pathogens, combination regimens are often employed in realworld settings. To assist the clinical decision-making process regarding the selection of combination antibiotics and dosages for this pathogen, we performed time-kill studies assessing clinical free peak and trough C/T concentrations alone and in combination with eight anti-pseudomonal agents against four clinical MDR PSA isolates.
Introduction
Conventionally, the success of antimicrobials against infectious organisms is dependent on their ability to inhibit bacterial growth and multiplication. 1 This inhibitory mechanism of action is antibiotic-specific, dependent on the antibiotic's structure, stability and affinity for specific bacterial target sites. 1 Bacteria, however, are constantly evolving, often decreasing the efficacy of antimicrobials over time via changes in bacterial target sites, enzyme production, porin mutations and efflux pumps leading to antimicrobial resistance. 2 The development of antimicrobialresistant organisms has left clinicians with limited therapeutic options. MDR Pseudomonas aeruginosa (PSA) is of particular concern, as it is a leading cause of nosocomial infections, which are often severe and life threatening. 3, 4 Rates of antibiotic resistance in PSA are increasing worldwide. 5, 6 Furthermore, MDR PSA has been shown to be independently associated with in-hospital mortality. 7 Carbapenems, such as meropenem, are often reserved for the treatment of highly resistant PSA, albeit, resistance has emerged. 8 Ceftolozane/tazobactam (C/T), is a novel broad-spectrum cephalosporin in combination with a b-lactamase inhibitor that has previously demonstrated activity against carbapenem-resistant PSA. 9, 10 Currently, the antibiotic is approved for the treatment of complicated urinary tract and complicated intra-abdominal infections at a dose of 1.5 g every 8 h (q8h). 11 Studies are ongoing for the treatment of ventilated nosocomial pneumonia at a dose of 3 g q8h (NCT no. 02070757). 12 Resistance mechanisms to currently available antimicrobials have been identified for all agents, including C/T. 13 However, combination antibiotic therapy is a potential strategy for increasing treatment efficacy and for preventing the evolution of resistance. 14 The goal of this strategy is to create a synergistic relationship, where the effect of two antimicrobials in combination is greater than the sum of the effects of each antimicrobial acting alone. 15, 16 Antimicrobial synergy is particularly of interest in the setting of antibiotic resistance, as monotherapy may not be sufficient in killing these burdensome organisms. Herein, we assessed the effect of achievable clinical concentrations of C/T, cefepime, ciprofloxacin, colistin, aztreonam, meropenem, piperacillin/tazobactam, fosfomycin and amikacin as monotherapy, dual therapy or triple therapy in an effort to elucidate synergistic regimens against MDR PSA, including isolates resistant to C/T.
Materials and methods

Microbiology
Four non-duplicate, clinical isolates of MDR PSA (resistance to at least three classes of antibiotics) were used in this study (PSA C8-21, PSA C28-5, PSA C45-10 and PSA C14-22). These isolates were selected to provide a phenotypic profile of C/T that was at or above the current breakpoint (4 mg/L), as higher MICs provide a better assessment of synergy with human drug exposures. Previous genetic testing identified PSA C45-10 and PSA C14-22 as OXA-50 b-lactamase producers.
Isolates were stored at the Center for Anti-Infective Research and Development (Hartford Hospital, Hartford, CT, USA) upon collection. 17 MICs of C/T, cefepime, ciprofloxacin, colistin, aztreonam, meropenem, piperacillin/tazobactam, fosfomycin and amikacin were determined in triplicate using broth microdilution according to CLSI guidelines. The modal MIC was reported. 18 Merck (Kenilworth, NJ, USA) provided ceftolozane powder; tazobactam and all other antibiotics were purchased from Sigma Chemical (St Louis, MO, USA).
Time-kill analyses
Time-kill analyses were performed on each of the four PSA isolates using free peak and trough concentrations of C/T and eight anti-pseudomonal antimicrobials alone and in combination. Each isolate was subcultured twice on trypticase soy agar with 5% sheep blood (Becton, Dickinson & Co., Sparks, MD, USA). Mueller-Hinton broth was inoculated with the bacterial suspension of 1%10 8 cfu/mL in 15 mL, colourless, screw-cap borosilicate glass culture tubes (Kimble-Chase, Vineland, NJ, USA). Control experiments without active compound were conducted simultaneously with the timekill studies. Final volumes for each bacterium-drug concentration were 10 mL and incubated at 37 C in a shaking water bath, as previously described. 19 Samples were taken from each culture tube at 0, 3, 6 and 24 h from the time of broth inoculation. Multiple 1:10 dilutions were made in saline and subcultured onto blood agar plates. Plates were incubated for 18-24 h and mean bacterial densities were determined for each isolate. The minimal, accurately countable number of cfu/mL (lower limit of detection) was determined to be 5%10 #1 cfu/mL. 19 All studies were conducted in duplicate and the combined data are presented as mean bacterial density (cfu/mL) for all isolates.
Monotherapy
To provide a baseline assessment of in vitro activity, three concentrations of C/T and two concentrations (peak and trough) of eight comparator antimicrobials were tested alone against the four PSA isolates. Antibiotic concentrations were chosen on the basis of free peak and free trough serum levels after standard intravenous administration: C/T 3 g q8h (peak: 120/25.2 mg/L; no trough), 11 C/T 1.5 g q8h (peak: 60/12.6; trough: 7.5/1.6 mg/L), 11 Dual therapy C/T 1.5 g q8h trough (referred to as C/T 7.5) was selected of the three C/T concentrations to assess better the synergy, as higher concentrations have notable kill as monotherapy. Both peak and trough concentrations of comparator antimicrobials were combined with C/T 7.5. Synergy was defined as a 2 log 10 decrease in cfu/mL between the antibiotic combination and its most active constituent after 24 h. An additive effect (1-2 log 10 decrease in cfu/mL between the antibiotic combination and its most active constituent after 24 h) was also noted.
Triple therapy
Triple therapy regimens were selected based on the degree of bacterial kill observed with monotherapy and dual therapy. Single agents or combination regimens that reached the lower limit of detection were not assessed in triple therapy regimens.
Results
In vitro susceptibility
Isolates had variable susceptibilities to C/T (range 4-16 mg/L). Table 1 displays the MDR phenotypic profiles of the four isolates.
Time-kill analyses
The free peak and trough concentrations corresponding to clinical doses for all antimicrobials are displayed in Table 2 . On average, the bacterial density of the unexposed control isolates grew 2 log 10 cfu at 24 h (Table 3) .
Monotherapy
The bacterial density at 24 h and the change in bacterial density from 0 h control for C/T, cefepime, ciprofloxacin, colistin, aztreonam, meropenem, piperacillin/tazobactam, fosfomycin and amikacin using peak and trough concentrations for each isolate are presented in Table 3 . For PSA C8-21 (C/T MIC 4), the change in bacterial density from 0 h for C/T 7.5, C/T 60 and C/T 120 were #0.10, #1.45 and #1.85 log 10 cfu, respectively ( Figure 1a ). Amikacin (peak) was the only agent to surpass the bacterial kill of C/T 120, reaching the lower limit of detection (#3.50 log 10 cfu change from 0 h). Ceftolozane/tazobactam synergy against MDR P. aeruginosa
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For PSA C28-5 (C/T MIC 4), the change in bacterial density from 0 h for C/T 7.5, C/T 60 and C/T 120 was #0.39, #0.81 and #2.75 log 10 cfu, respectively ( Figure 2a ). Comparable to the previous isolate, amikacin (peak) was the only agent to surpass the bacterial kill of C/T 120, reaching the lower limit of detection (#3.61 log 10 cfu change from 0 h).
Against PSA C45-10 (C/T MIC 8), the change in bacterial density from 0 h for C/T 7.5, C/T 60 and C/T 120 were #0.39, #2.57 and #3.66 log 10 cfu, respectively (Figure 3a) . Similar to C/T 120, ciprofloxacin (peak), meropenem (peak) and amikacin (peak) reached the lower limit of detection.
Against PSA C14-22 (C/T MIC 16), the change in bacterial density from 0 h for C/T 7.5, C/T 60 and C/T 120 were 1.02, #0.10 and #2.37 log 10 cfu, respectively (Figure 4a). Ciprofloxacin (peak) and amikacin (peak) reached the lower limit of detection against PSA C14-22, producing identical bacterial density reductions of #3.61 log 10 cfu. Of the trough concentrations, no notable decreases in bacterial burden were observed.
Dual therapy
Against PSA C8-21, all comparator peak concentrations plus C/T 7.5 improved the bacterial reduction compared with either agent alone. Cefepime, ciprofloxacin and fosfomycin peak concentrations with C/T 7.5 resulted in 1-2 log 10 cfu decrease in bacterial burden at 24 h. Colistin peak concentration plus C/T 7.5 was synergistic, reaching the lower limit of detection. Similar findings were observed with comparator trough concentration combinations as all combinations improved bacterial kill, with the exception of piperacillin/tazobactam plus C/T 7.5. Colistin (trough) with C/T 7.5 was additive (Figure 1b and c) .
The majority of comparator peak concentrations plus C/T 7.5 combinations further enhanced the bacterial kill against PSA C28-5, with the exception of ciprofloxacin plus C/T 7.5. Colistin and fosfomycin (peak) with C/T 7.5 were synergistic achieving 24 h log 10 cfu reduction of #3.61 and #2.80, respectively (Figure 2b and c) . Three of the eight trough combinations (amikacin, fosfomycin and colistin) improved the 24 h bacterial burden, with colistin (trough) and C/T 7.5 resulting in synergy.
Of the peak combinations, colistin plus C/T 7.5 was the only dual therapy to be synergistic against PSA C45-10. Notably, meropenem and amikacin peak concentrations alone reached the lower limit of detection; therefore, synergy could not be determined. However, when the trough concentrations were used in combination with C/T 7.5, we observed synergy with colistin, meropenem and amikacin with bacterial reductions at 24 h of #3.41, #3.28 and #3.66 log 10 cfu, respectively (Figure 3b and c) .
Unlike the observed lack of efficacy against previous isolates, piperacillin/tazobactam peak and aztreonam peak and trough combinations with C/T 7.5 demonstrated improved bacterial kill against PSA 14-22 compared with either agent alone. Furthermore, fosfomycin peak and trough combinations with C/T 7.5 resulted in .2 and 1.94 log 10 cfu increase in bacterial reduction, respectively, compared with either agent alone, similar to the observation against PSA C28-5. Again, colistin (trough) plus C/T 7.5 was synergistic (Figure 4b and c).
Triple therapy
Of the triple therapies tested, colistin plus fosfomycin plus C/T 7.5 was synergistic against two of two isolates (PSA C8-21 and PSA C14-22; Figure 5a and c). Amikacin plus fosfomycin plus C/T 7.5 was synergistic in one of three isolates tested (PSA C14-22; Figure 5b ).
Discussion
Combining antimicrobials with different mechanisms of action may increase the likelihood of treatment success against MDR organisms. 33 In our study, we evaluated therapeutic concentrations of C/T (1.5 and 3 g q8h) and eight other antimicrobials against MDR PSA to assist in the selection of optimal C/T doses and to detect synergistic combination therapies. These data suggest C/T 1.5 and 3 g q8h peak concentrations demonstrate bacterial efficacy against these MDR isolates with C/T MICs between 4 and 16 mg/L. Furthermore, C/T with colistin and/or fosfomycin was synergistic in vitro.
The current FDA, EUCAST and CLSI C/T breakpoints for PSA are 4/4 mg/L. 18, 34 As C/T has displayed high in vitro potency against PSA, 9 we selected isolates at or above the breakpoint to assess synergy. Importantly, PSA with C/T MICs of 4/4 mg/L represent only 5% of the population and isolates with MICs of 8 and 16 mg/L represent only 1% each of the MIC distribution. 9 Our findings suggest C/T 3 or 1.5 g q8h dose may be effective against isolates at or one dilution higher than the breakpoint, given both peak (C/T 120 mg/L) and trough (C/T 7.5 mg/L) concentrations reduced the bacterial density over 24 h against isolates with MICs of 4 and 8 mg/L.
We recognize our concentrations were static and did not account for human pharmacokinetic/pharmacodynamic exposures; however, these findings are further supported in vivo by a previous population pharmacokinetic model. Using a threshold of 60% free time above MIC (fT .MIC ), a 1.5 and 3 g q8h C/T regimen was found to achieve a PTA of 90% at MICs up to 4 and 8 mg/L, respectively. 35 No activity was observed with the trough Monogue and Nicolau .2 log 10 cfu/mL decrease from the most active agent (synergistic).
Ceftolozane/tazobactam synergy against MDR P. aeruginosa JAC concentration of C/T 1.5 g q8h (C/T 7.5) against PSA with an MIC of 16 mg/L, as drug concentrations were never near or above the MIC. Among all four isolates, the extent of bacterial kill was improved with increasing concentrations of C/T. Overall, the efficacy of the peak concentrations of the comparator agents alone was reflective of their corresponding MIC. For instance, all PSA isolates were amikacin susceptible (MIC 16 mg/L); therefore, amikacin peak concentrations demonstrated .3 log 10 cfu reduction in bacterial density over 24 h against the four PSA isolates. However, the trough concentrations of these comparator agents alone were not effective regardless of MIC, as the concentrations were not sufficient to achieve their respective pharmacokinetic/pharmacodynamic target indices.
C/T 7.5 was used for the synergy studies due its limited efficacy against the MDR PSA alone, allowing for synergy to be evaluated with other agents. Furthermore, concentrations of 7.5 mg/L are frequently achieved and maintained throughout the duration of therapy in various patient populations, assuring a conservative clinical approach in the evaluation of these therapeutic regimens.
11,35-37 Importantly, for those agents reaching the lower Monogue and Nicolau limit of detection as monotherapy, we were not able to assess synergy, as demonstrated with amikacin peak concentrations. C/T 7.5 plus colistin peak and trough concentrations were the most frequent synergistic combinations, followed by fosfomycin peak concentrations. Of note, dual b-lactam therapy was not impressive compared with the agents alone, suggesting the use of antimicrobials with mechanisms of action differing from C/T have the greatest potential for synergy. Triple therapy was conducted to assess whether the degree of bacterial killing could be enhanced.
Reflective of the dual therapy findings, fosfomycin plus colistin plus C/T 7.5 demonstrated synergy in two of two isolates tested.
In vitro synergy of C/T with another antimicrobial has yet to be demonstrated. 38 In previous time-kill experiments, both colistin and fosfomycin combinations demonstrated synergy against carbapenem-resistant Klebsiella pneumoniae and PSA. [39] [40] [41] Furthermore, various colistin combinations, such as colistin plus tigecycline, meropenem or daptomycin, were synergistic against Acinetobacter baumannii and PSA. Ceftolozane/tazobactam synergy against MDR P. aeruginosa
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Intravenous fosfomycin is currently not available in the USA, but is under development. 45 Colistin, once previously ignored due to fears surrounding renal toxicity, has re-emerged into clinical practice given its in vitro potency against MDR organisms. 46 Nevertheless, there are concerns surrounding colistin's pharmacokinetics/pharmacodynamics in various patient populations, specifically regarding achievable concentrations in relation to the established breakpoint of 2 mg/L. 34, 47 Recognizing these difficulties, it is important to acknowledge our data demonstrated C/T and colistin synergy at colistin concentrations as low as 0.5 mg/L. To the best of our knowledge, this is the first study assessing synergy of C/T against Gram-negative organisms. C/T 3 and 1.5 g q8h peak concentrations demonstrate killing against MDR PSA isolates at or above the clinical breakpoint. Colistin and fosfomycin were synergistic with C/T in vitro. Our findings will aid in the identification of novel treatment options and available drug (c) Figure 5 . Time-kill experiments displaying the activity of antimicrobials alone and in combination at peak and trough concentrations against three PSA isolates. CST, colistin; FOF, fosfomycin; AMK, amikacin.
